HighField Biopharmaceuticals Seeks NMPA’s IND Clearance for HF158K1 & HFK2 to Treat Solid Tumors
Shots:
- China’s NMPA has received 2 IND applications for HF158K1 (K1) & HFK2 (K2) to initiate P-I dose escalation trial in China to evaluate safety & PK of K1 alone & its preliminary efficacy with K2 to treat pts with solid tumors refractory to prior therapies
- Preclinical studies of K1, K2, & their combination showed superior efficacy than marketed HER2-targeting ADCs in mouse tumor models, with wider efficacy to maximum tolerant dose therapeutic windows; K1 is being investigated as monotx. in an ongoing P-I trial in the US
- Derived from HighField’s ADCplex platform, HF158K1 & HFK2 contains Topoisomerase I & II inhibitors as payloads, respectively, & are equipped with HER2 antibodies to target HER2 receptors in both high & low HER2-expressing tumors
Ref: Businesswire | Image: HighField Biopharmaceuticals
Related News:- GSK Receives the MHRA’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
